In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Elanco Animal Health Inc (NYSE: ELAN) closed at $17.35 down -2.80% from its previous closing price of $17.85. In other words, the price has decreased by -$2.80 from its previous closing price. On the day, 6.43 million shares were traded. ELAN stock price reached its highest trading level at $17.855 during the session, while it also had its lowest trading level at $17.13.
Ratios:
For a deeper understanding of Elanco Animal Health Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.88. For the most recent quarter (mrq), Quick Ratio is recorded 1.40 and its Current Ratio is at 2.60. In the meantime, Its Debt-to-Equity ratio is 0.62 whereas as Long-Term Debt/Eq ratio is at 0.61.
On December 09, 2024, UBS started tracking the stock assigning a Buy rating and target price of $18.UBS initiated its Buy rating on December 09, 2024, with a $18 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 11 ’25 when Todd S and Jennifer G Young Li bought 49,333 shares for $16.82 per share.
Kurzius Lawrence Erik bought 10,000 shares of ELAN for $109,000 on Mar 07 ’25. The Director now owns 101,459 shares after completing the transaction at $10.90 per share. On Mar 11 ’25, another insider, Kurzius Lawrence Erik, who serves as the Director of the company, bought 10,000 shares for $10.20 each. As a result, the insider paid 102,000 and bolstered with 111,459 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELAN now has a Market Capitalization of 8619723776 and an Enterprise Value of 12289717248. As of this moment, Elanco’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.88, and their Forward P/E ratio for the next fiscal year is 17.58. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.68. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.92 while its Price-to-Book (P/B) ratio in mrq is 1.27. Its current Enterprise Value per Revenue stands at 2.741 whereas that against EBITDA is 14.596.
Stock Price History:
The Beta on a monthly basis for ELAN is 1.64, which has changed by 0.13029313 over the last 52 weeks, in comparison to a change of 0.1716845 over the same period for the S&P500. Over the past 52 weeks, ELAN has reached a high of $18.87, while it has fallen to a 52-week low of $8.02. The 50-Day Moving Average of the stock is 10.60%, while the 200-Day Moving Average is calculated to be 36.81%.
Shares Statistics:
For the past three months, ELAN has traded an average of 6.94M shares per day and 15011610 over the past ten days. A total of 496.65M shares are outstanding, with a floating share count of 492.13M. Insiders hold about 0.94% of the company’s shares, while institutions hold 108.99% stake in the company. Shares short for ELAN as of 1755216000 were 24292849 with a Short Ratio of 3.50, compared to 1752537600 on 23568194. Therefore, it implies a Short% of Shares Outstanding of 24292849 and a Short% of Float of 6.760000400000001.
Earnings Estimates
The current rating of Elanco Animal Health Inc (ELAN) reflects the combined expertise of 10.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.13, with high estimates of $0.15 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.91 and $0.82 for the fiscal current year, implying an average EPS of $0.88. EPS for the following year is $0.99, with 13.0 analysts recommending between $1.05 and $0.95.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $1.09B this quarter.It ranges from a high estimate of $1.1B to a low estimate of $1.08B. As of the current estimate, Elanco Animal Health Inc’s year-ago sales were $1.03BFor the next quarter, 8 analysts are estimating revenue of $1.08B. There is a high estimate of $1.09B for the next quarter, whereas the lowest estimate is $1.06B.
A total of 11 analysts have provided revenue estimates for ELAN’s current fiscal year. The highest revenue estimate was $4.62B, while the lowest revenue estimate was $4.47B, resulting in an average revenue estimate of $4.59B. In the same quarter a year ago, actual revenue was $4.44BBased on 11 analysts’ estimates, the company’s revenue will be $4.81B in the next fiscal year. The high estimate is $4.89B and the low estimate is $4.65B.
